CA3147106A1 - Inhibitors of cyclin-dependent kinase 7 and uses thereof - Google Patents
Inhibitors of cyclin-dependent kinase 7 and uses thereof Download PDFInfo
- Publication number
- CA3147106A1 CA3147106A1 CA3147106A CA3147106A CA3147106A1 CA 3147106 A1 CA3147106 A1 CA 3147106A1 CA 3147106 A CA3147106 A CA 3147106A CA 3147106 A CA3147106 A CA 3147106A CA 3147106 A1 CA3147106 A1 CA 3147106A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- substituted
- unsubstituted
- pharmaceutically acceptable
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877788P | 2019-07-23 | 2019-07-23 | |
| US62/877,788 | 2019-07-23 | ||
| PCT/US2020/043132 WO2021016388A1 (en) | 2019-07-23 | 2020-07-22 | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3147106A1 true CA3147106A1 (en) | 2021-01-28 |
Family
ID=74192704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3147106A Pending CA3147106A1 (en) | 2019-07-23 | 2020-07-22 | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230242534A9 (https=) |
| EP (1) | EP4003335A4 (https=) |
| JP (1) | JP7680999B2 (https=) |
| CN (1) | CN114401719A (https=) |
| AU (1) | AU2020319005B2 (https=) |
| CA (1) | CA3147106A1 (https=) |
| WO (1) | WO2021016388A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| US20230114207A1 (en) * | 2019-12-24 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| ES2661883T3 (es) * | 2012-07-09 | 2018-04-04 | Novartis Ag | Biomarcadores asociados con inhibidores de CDK |
| AU2015371251B2 (en) * | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) * | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
-
2020
- 2020-07-22 EP EP20843441.5A patent/EP4003335A4/en active Pending
- 2020-07-22 CA CA3147106A patent/CA3147106A1/en active Pending
- 2020-07-22 CN CN202080052924.XA patent/CN114401719A/zh active Pending
- 2020-07-22 WO PCT/US2020/043132 patent/WO2021016388A1/en not_active Ceased
- 2020-07-22 JP JP2022504701A patent/JP7680999B2/ja active Active
- 2020-07-22 AU AU2020319005A patent/AU2020319005B2/en active Active
- 2020-07-22 US US17/628,794 patent/US20230242534A9/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7680999B2 (ja) | 2025-05-21 |
| EP4003335A4 (en) | 2024-01-10 |
| AU2020319005A1 (en) | 2021-12-23 |
| JP2022541644A (ja) | 2022-09-26 |
| AU2020319005B2 (en) | 2026-01-08 |
| US20230242534A9 (en) | 2023-08-03 |
| WO2021016388A1 (en) | 2021-01-28 |
| EP4003335A1 (en) | 2022-06-01 |
| CN114401719A (zh) | 2022-04-26 |
| US20220281874A1 (en) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12168663B2 (en) | Inhibitors of cyclin-dependent kinase 7 (CDK7) | |
| CA2978518C (en) | Inhibitors of cyclin-dependent kinases | |
| AU2020319005B2 (en) | Inhibitors of cyclin-dependent kinase 7 and uses thereof | |
| AU2019413694B2 (en) | Inhibitors of cyclin-dependent kinase 7 and uses thereof | |
| US10342798B2 (en) | Fused bicyclic pyrimidine derivatives and uses thereof | |
| AU2020357983B2 (en) | Tricyclic kinase inhibitors and uses thereof | |
| WO2016065138A1 (en) | Thiazolyl-containing compounds for treating proliferative diseases | |
| CA2988330C (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| CA2988330A1 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| HK1245260B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240613 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250707 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250718 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251106 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251231 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251231 |